Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 9/20 | 0.37 |
| ▸ | CA2 | P00918 | 9/20 | 0.37 |
| ▸ | CA9 | Q16790 | 7/20 | 0.37 |
| ▸ | CA12 | O43570 | 6/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL820100 | 0.84 | ALDH1A1 (0.42) | ALDH1A1LMNAKDM4EHPGD | |
| SCHEMBL8461792 | 0.83 | CA1 (0.37) | CA1CA2CA9CA12ALDH1A1 | |
| SCHEMBL818820 | 0.77 | CYP3A4 (0.47) | CA2ALDH1A1HSD17B10LMNA | |
| SCHEMBL24471528 | 0.77 | ALDH1A1 (0.38) | CA1CA2CA9CA12ALDH1A1 | |
| SCHEMBL6836214 | 0.77 | PPM1B (0.42) | ALDH1A1HSD17B10LMNAMAPTKDM4E | |
| SCHEMBL6821920 | 0.77 | PPM1B (0.42) | ALDH1A1HSD17B10LMNAMAPTKDM4E | |
| SCHEMBL17066781 | 0.75 | ALDH1A1 (0.37) | ALDH1A1HSD17B10LMNAMAPTKDM4E | |
| SCHEMBL7234184 | 0.75 | ALDH1A1 (0.37) | ALDH1A1HSD17B10LMNAMAPTKDM4E | |
| SCHEMBL7234598 | 0.75 | ALDH1A1 (0.37) | ALDH1A1HSD17B10LMNAMAPTKDM4E | |
| SCHEMBL1169711 | 0.75 | MEN1 (0.36) | CA1CA2CA9CA12ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367858-B2 | Terephthalic and trimellitic based acids and carboxylate derivatives thereof | Amyris, Inc. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20110288311-A1 | NOVEL TEREPHTHALIC AND TRIMELLITIC BASED ACIDS AND CARBOXYLATE DERIVATIVES THEREOF | DRATHS CORPORATION (US) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288311-A1 | NOVEL TEREPHTHALIC AND TRIMELLITIC BASED ACIDS AND CARBOXYLATE DERIVATIVES THEREOF | TRIM4, DDT, PICALM | CA1 1139/4885CA2 1736/4885CA9 2178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.